Seagen Inc - Company Profile
Powered by 
All the data and insights you need on Seagen Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Seagen Inc Strategy Report
- Understand Seagen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Seagen Catalyst Calendar
Proactively evaluate Seagen Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Seagen Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 28 Sep 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 24 Sep 2019 | Phase II Trial Completion | Fondazione Italiana Linfomi ONLUS; Millennium Pharmaceuticals Inc; Seagen Inc; Takeda Pharmaceutical Co Ltd | 4502; SGEN | brentuximab vedotin | Oncology | Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy; Peripheral T-Cell Lymphomas (PTCL); Transformed Mycosis Fungoides | Clinical Trial Registry |
| 01 Sep 2019 | Phase I Trial Initiation | Seagen Inc | SGEN | SGNCD-228A | Oncology | Breast Cancer; Breast Tumor; Colorectal Cancer; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Malignant Pleural Mesothelioma; Melanoma; Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Solid Tumor | Clinical Trial Registry |
| 01 Sep 2019 | Phase II Trial Initiation | Seagen Inc | SGEN | brentuximab vedotin | Oncology | Anaplastic Large Cell Lymphoma (ALCL); Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma); Peripheral T-Cell Lymphomas (PTCL) | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer